Breaking News | Nektar Therapeutics Announces Six Abstracts Accepted for Presentation at the 2018 A

Nektar Therapeutics & Bristol-Myers Squibb, Deal of the Year | PANTHEON 2018 PRESENTING DiNA™ AWARDSПодробнее

Nektar Therapeutics and HealthiVibe: The Summit - Rising Together with PatientsПодробнее

NEKTAR THERAPEUTICS Company Profile and Tech Intelligence Report, 2018Подробнее

Nektar’s Opioid Analgesic Meets Endpoints in Phase III Clinical TrialПодробнее

The future of cancer care: Using the body's immune systemПодробнее

2018 Nektar TherapeuticsПодробнее

Nektar Therapeutics 2022 J P Morgan PresentationПодробнее

Study shows potential danger of new artificial sweetenerПодробнее

Mayor Newsom Celebrates Grand Opening of Nektar Therapeutics HeadquartersПодробнее

IH 2018 Opening speech Dr. Patrice Matchaba, NovartisПодробнее

COO of Nektar Therapeutics Leaving Post in January (NKTR)Подробнее

🔴 Nektar Therapeutics NKTR Stock Trading Facts 🔴Подробнее

PIVOT IO 009 TrialПодробнее

Nektar Therapeutics (NKTR) loses 61% in a Single Day after Disappointing Melanoma TrialПодробнее

12) Panel Discussion Promoting early diagnosis of hATTR /ATTRv-PN -Updates in Amyloidosis (2.3.2024)Подробнее

NKTR Breakout ComingПодробнее

Nektar Therapeutics NKTR Q2 2024 Earnings PresentationПодробнее

[NKTR stock] Nektar Therapeutics Q4 2020 Earnings Call (2/25/21)Подробнее

Biotech Firm Nektar Therapeutics Explores Partnership OptionsПодробнее